Methioninase Gene Therapy for Malignant Tumor Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for malignant tumors, such as surgery and chemical drug therapy, often have adverse reactions, limited efficacy, and can lead to drug resistance, necessitating the development of new targeting and precision medicine approaches, particularly in addressing the unique metabolic needs of tumor cells.
Innovation Solution
A viral vector system expressing the methionine γ-lyase gene (MEGL) is used to inhibit the expression and activity of methyltransferase EZH2, leveraging methionine metabolism to inhibit tumor growth and metastasis, utilizing a lentivirus vector with an EF1A promoter and mCherry fluorescent protein for targeted gene delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If exogenous methioninase is administered to decompose methionine and inhibit tumor cell growth, then tumor cell proliferation is delayed, but immune reactions and side effects occur in the body
Solution Approach 1:
The patent uses a viral vector as an intermediary carrier to deliver the methioninase gene into tumor cells. The viral vector acts as a mediator that enables endogenous expression of methioninase within the tumor cells, avoiding the need for exogenous enzyme administration and the associated immune reactions while achieving sustained methionine decomposition and tumor growth inhibition
Solution Approach 2:
The patent enables tumor cells to self-produce methioninase through genetic modification. By introducing the methioninase gene into tumor cells via viral vector, the tumor cells themselves become the source of methioninase production, continuously decomposing methionine and inhibiting their own proliferation without requiring external enzyme supplementation or triggering immune responses
2Reliability
If dietary methionine is restricted to delay tumor cell proliferation, then tumor growth is inhibited, but malnutrition and metabolic disorders occur
Solution Approach 1:
The patent applies methionine decomposition locally within tumor cells through targeted gene delivery. The methioninase gene is specifically introduced into tumor cells, enabling methionine breakdown only in the tumor microenvironment while leaving normal cells with intact methionine metabolism, thus inhibiting tumor growth without causing systemic malnutrition or metabolic disorders
Solution Approach 2:
The viral vector serves as an intermediary to deliver the methioninase gene specifically to tumor cells. This targeted delivery mechanism ensures that methionine decomposition occurs selectively in tumor cells rather than systemically, preventing the metabolic disorders and malnutrition that would result from broad methionine restriction
3Reliability
If conventional treatments such as surgery and chemical drug therapy are used to treat malignant tumors, then tumor removal or inhibition is achieved, but adverse reactions and drug resistance occur
Solution Approach 1:
The patent exploits the metabolic vulnerability of tumor cells as a weapon against them. By introducing methioninase gene into tumor cells, the treatment converts the cells' high methionine dependence (which supports their rapid growth) into their Achilles' heel, causing methionine depletion and growth inhibition while sparing normal cells that are less dependent on methionine
Solution Approach 2:
The treatment modifies tumor cells to self-destruct through metabolic collapse. The introduced methioninase gene enables tumor cells to autonomously decompose their essential amino acid methionine, leading to self-inhibition of proliferation and eventual cell death without requiring continuous external drug administration or causing systemic toxicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MEGL-expressing viral vector effectively reduces intracellular methionine levels and inhibits EZH2 expression, leading to significant inhibition of tumor cell proliferation and metastasis with minimal cytotoxicity and immune response, offering a precise and effective treatment for various malignant tumors.
Implementation Method 1
reducing methionine in vivo through the specific decomposition of methionine by methioninase MEGL
Implementation Method 2
viral vectors were constructed by inserting exogenous MEGL gene to express methioninase
Data Source
AI summary
Disclosed is an application of methioninase gene therapy in the treatment of a malignant tumor. In the gene therapy, a virus is used as a vector to insert an exogenous methioninase gene to constitute a methioninase expression system inside a tumor, thus providing an endogenous mechanism for further consumption of methionine. In vitro cytology experiments indicate that the methioninase gene therapy significantly reduces the level of intracellular methionine, effectively inhibits the proliferation of tumor cells, and can be used in an application in preparing a drug for the targeted treatment of a malignant tumor.